EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24
https://www.ema.europa.eu/en/medicines/human/variation/dupixent
Sanofi decided to stop trying to get approval for one of its medicines to treat a rare skin disease in Europe. When companies withdraw applications like this, it usually means they found problems or decided it wasn't worth continuing, so it's worth watching to see if the company explains why.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.